Future studies employing metabolic syndrome-associated MASH models will be valuable to confirm the therapeutic potential of Alisol F 24-acetate in a more clinically representative context and to further validate the role of the KEAP1/NRF2 axis in macrophage pyroptosis across different disease etiologies. This evidence concerns the gene KEAP1 and metabolic syndrome.